Inhibition of constitutive and cxc-chemokine-induced NF-B activity potentiates ansamycin-based HSP90-inhibitor cytotoxicity in castrate-resistant prostate cancer cells

British Journal of Cancer

Volumn 101, Issue 9, 2009, Pages 1620-1629

  Seaton, A ^a   Maxwell, P J ^a   Hill, A ^a   Gallagher, R ^a   Pettigrew, J ^a   Wilson, R H ^a   Waugh, D J J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

CXC chemokines; CXCL8; Hsp90 inhibitors; NF kB; Prostate cancer

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; 5 [[(3 CHLORO 2 FLUOROPHENYL)METHYL]THIO] 7 [(2 HYDROXY 1 METHYLETHYL)AMINO]THIAZOLO[4,5 D]PYRIMIDIN 2(3H) ONE; AZ 10397767; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CXCR2; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LUCIFERASE; MESSENGER RNA; TANESPIMYCIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CASTRATION; CELL ASSAY; CELL DEATH; CELL VIABILITY; CHEMOSENSITIZATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DU145 CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE REPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; PC3 CELL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 70350654366     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605356     Document Type: Article

References (39)

1. Araki S, Omori Y, Lyn D, Singh RK, Meinbach DM, Sandman Y, Lokeshwar VB, Lokeshwar BL (2007) Interleukin-8 is a molecular determinant of androgen-independence and progression in prostate cancer. Cancer Res 67: 6854-6862
2. Fradet V, Lessard L, Begin LR, Karakiewicz P, Masson AM, Saad F (2004) Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res 10: 8460-8464
3. Huang J, Yao JL, Zhang L, Bourne PA, Quinn AM, di Sant'Agnese PA, Reeder JE (2005a) Differential expression of Interleukin-8 and its receptors in the neuroendocrine and non-neuroendocrine compartments of prostate cancer. Am J Pathol 166: 1807-1815
4. Huang YT, Pan SL, Guh JH, Chang YL, Lee FY, Kuo SC, Teng CM (2005b) YC-1 suppresses constitutive nuclear factor-kappaB activation and induces apoptosis in human prostate cancer cells. Mol Cancer Ther 4: 1628-1635
5. Inoue K, Slaton JW, Eve BY, Kim SJ, Perrotte P, Balbay MD, Yano S, Bar-Eli M, Radinsky R, Pettaway CA, Dinney CP (2000) Interleukin-8 expression regulates tumourigenicity and metastases in androgen-independent CaP. Clin Cancer Res 6: 2104-2119
6. Isaacs JS, Xu W, Neckers L (2003) Heat shock protein 90 as a molecular target for cancer therapeutics. Cancer Cell 3: 213-217
7. Jolly C, Morimoto RI (2000) Role of the heat shock response and molecular chaperones in oncogenesis and cell death. J Natl Cancer Inst 92: 1564-1572
8. Kim SJ, Uehara H, Karashima T, McCarty M, Shih N, Fidler IJ (2001) Expression of interleukin-8 correlates with angiogenesis, tumourigenicity and metastasis of human CaP cells implanted orthotopically in nude mice. Neoplasia 3: 33-42
9. Lecoeur H, Melki MT, Saidi H, Gougeon ML (2008) Analysis of apoptotic pathways by multiparametric flow cytometry: application to HIV-infection. Methods Enzymology 442: 51-82
10. Li Y, Ahmed F, Ali S, Philip PA, Kucuk O, Sarkar FH (2005) Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 65: 6934-6942
11. MacManus CF, Pettigrew J, Seaton A, Wilson C, Maxwell PJ, Berlingeri S, Purcell C, McGurk M, Johnston PG, Waugh DJ (2007) Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 5: 737-748
12. Maloney A, Workman P (2002) Hsp90 as a new therapeutic target for cancer therapy: the story unfolds. Exp Opin Biol Ther 2: 3-24
13. Maxwell PJ, Gallagher R, Seaton A, Wilson C, Scullin P, Pettigrew J, Stratford IJ, Williams KJ, Johnston PG, Waugh DJ (2007) HIF-1 and NK-kB-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic CaP cells. Oncogene 26: 7333-7345
14. Meyer P, Prodromou C, Hu B, Vaughan C, Panaretou B, Piper WP, Pearl LH (2003) Structural and functional analysis of the middle segment of Hsp90: implications of ATP hydrolysis and client protein and cochaperone interactions. Mol Cell 11: 647-658
15. Mimnaugh EG, Chavany C, Neckers L (1996) Polyubiquitination and proteasomal degradation of the p185c-erbB-2 receptor protein tyrosine kinase induced by geldanamycin. J Biol Chem 271: 22796-22801
16. Munster PN, Basso A, Solit D, Norton L, Rosen N (2001) Modulation of Hsp90 function by ansamycins sensitises breast cancer cells to chemotherapy-induced apoptosis in an RB-and schedule dependent manner. Clin Cancer Res 7: 2228-2236
17. Murphy C, McGurk M, Pettigrew J, Santinelli A, Mazzucchelli R, Johnston PG, Montironi R, Waugh DJ (2005) Non-apical and cytoplasmic expression of interleukin-8, CXCR1 and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-4127
18. Pacey S, Banerji U, Judson I, Workman P (2006) Hsp90 inhibitors in the clinic. Handb Exp Pharmacol 172: 331-358
19. Pacey SC, Wilson R, Walton M, Eatock M, Zetterlund H, Arkenau H, Beecham R, Raynaud F, Workman P, Judson I (2009) A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. Proc Am Soc Clin Onc (In press
20. Rakitina TV, Vasilevskaya IA, O'Dwyer PJ (2003) Additive interaction of oxaliplatin and 17-allylamino-17-demethoxygeldanamycin in colon cancer cells lines results from inhibition of nuclear factor kB signalling. Cancer Res 63: 8600-8605
21. Ramanthan RK, Egorin MJ, Eiseman JL, Ramdingam S, Friedland D, Agarwala SS, Ivy SP, Potter DM, Chatta G, Zukowski EG, Stoller RG, Naret C, Guo J, Belani CP (2007) Phase I and pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 13: 1769-1774 (Pubitemid 46952944)
22. Roe SM, Prodromou C, O'Brien R, Ladbury JE, Piper PW, Pearl LH (1999) The structural basis for inhibition of the Hsp90 molecular chaperone by the anti-tumour antibiotics radicicol and geldanamycin. J Med Chem 42: 260-266
23. Sausville EA, Tomaszewski JE, Ivy P (2003) Clinical development of 17-allylamino, 17-demethoxygeldanamycin. Curr Cancer Drug Targets 3: 377-383
24. Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJJ (2008) Interleukin-8 signalling promotes androgen independent growth of CaP cells via induction of androgen receptor expression and activation. Carcinogenesis 29: 1148-1156
25. Smith DF, Whitesell L, Katsanis E (1998) Molecular chaperones: biology and prospects for pharmacological intervention. Pharmacol Rev 50: 493-513
26. Solit DB, Rosen N (2003) Hsp90 as a therapeutic target in CaP. Semin Oncol 30: 709-716
27. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF, Kelly WK, DeLaCruz A, Curley T, Heller G, Larson S, Schwartz L, Egorin MJ, Rosen N, Scher HI (2007) Phase I trial of 17-allylamino-17-demethox-ygeldanamycin in patients with advanced cancer. Clin Cancer Res 13: 1775-1782 (Pubitemid 46952945)
28. Solit DB, Zheng FF, Drobnjak M, Munster PN, Higgins B, Verbel D, Heller G, Tong W, Cordon-Cardo C, Agus DB, Scher HI, Rosen N (2002) 17-allylamino-17-demethoxygeldanamycin induces the degradation of androgen receptor and HER-2/neu and inhibits the growth of CaP xenografts. Clin Cancer Res 8: 986-993
29. Solit SB, Rosen N (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6: 1205-1214
30. Sweeney C, Li L, Shanmugam R, Bhat-Nakshatri P, Jayaprakasan V, Baldridge LA, Gardner T, Smith M, Nakshatri H, Cheng L (2004) Nuclear factor-kappaB is constitutively activated in prostate cancer in vitro and is overexpressed in prostatic intraepithelial neoplasia and adenocarcinoma of the prostate. Clin Cancer Res 10: 5501-5507
31. Uehara H, Troncoso P, Johnston D, Bucana CD, Dinney C, Dong Z, Fidler IJ, Pettaway CA (2005) Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage. Prostate 64: 40-49
32. Vasilevskaya IA, O'Dwyer PJ (2005) 17-Allylamino-17-demethoxygeldana- mycin overcomes TRAIL resistance in colon cancer cell lines. Biochem Pharm 71: 580-589
33. Veltri RW, Miller MC, Partin AW, Poole EC, O'Dowd GJ (1999) Interleukin-8 serum levels in patients with benign prostatic hyperplasia and CaP. Cancer 91: 2322-2328
34. Walters IA, Austin C, Austin R, Bonnert R, Cage P, Christie M, Ebden M, Gardiner S, Grahames C, Hill S, Hunt F, Jewell R, Lewis S, Martin I, Nicholls D, Robinson D (2007) Structure-activity relationships of a series of thiazolopyrimidine-based CXCR2 antagonists. Bioorg Med Chem Lett 18: 798-803
35. Waugh DJ, Wilson C (2008) The Interleukin-8 signaling pathway in cancer. Clin Cancer Res 14: 6735-6741
36. Waugh DJ, Wilson C, Seaton A, Maxwell PJ (2008) Multi-faceted roles for CXC-chemokines in prostate cancer progression. Front Biosci 13: 4594-4604
37. Wilson C, Seaton A, Purcell C, Oladipo B, Pettigrew J, Maxwell PJ, Scullin P, O'Sullivan JM, Wilson RH, Johnston PG, Waugh DJJ (2008a) Chemotherapy-induced CXC-chemokine/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis. J Pharmacol Exp Ther 327: 746-759
38. Wilson C, Wilson T, Johnston PG, Longley DB, Waugh DJJ (2008b) Interleukin-8 signaling attenuates TRAIL and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol Cancer Ther 7: 2649-2661
39. Workman P (2004) Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone. Cancer Lett 206: 149-157